Aurinia Pharmaceuticals Number Of Shares Shorted vs. Cash Flow From Operations
| AUPH Stock | USD 9.20 0.22 2.45% |
For Aurinia Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aurinia Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aurinia Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aurinia Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aurinia Pharmaceuticals over time as well as its relative position and ranking within its peers.
Aurinia |
Aurinia Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Aurinia Pharmaceuticals Cash Flow From Operations vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Aurinia Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aurinia Pharmaceuticals value to that of its competitors to determine the firm's financial worth.Aurinia Cash Flow From Operations vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Aurinia Pharmaceuticals |
| = | 5.53 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Aurinia Pharmaceuticals |
| = | (33.46 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Aurinia Cash Flow From Operations Comparison
Aurinia Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers.
Aurinia Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Aurinia Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aurinia Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Aurinia Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Aurinia Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -730 K | -766.5 K | |
| Operating Income | -91.7 M | -87.1 M | |
| Income Before Tax | -77.5 M | -73.6 M | |
| Total Other Income Expense Net | 14.2 M | 14.9 M | |
| Net Loss | -78 M | -74.1 M | |
| Income Tax Expense | 551 K | 1.1 M | |
| Net Loss | -77.2 M | -73.3 M | |
| Net Loss | -97.4 M | -92.5 M | |
| Interest Income | 15.3 M | 16.1 M | |
| Net Interest Income | 13.9 M | 14.6 M | |
| Non Operating Income Net Other | 476.1 K | 818 K | |
| Change To Netincome | 37.7 M | 39.6 M | |
| Net Loss | (0.54) | (0.57) | |
| Income Quality | 0.43 | 0.41 | |
| Net Income Per E B T | 1.01 | 1.06 |
Aurinia Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Aurinia Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aurinia Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aurinia Pharmaceuticals' important profitability drivers and their relationship over time.
Use Aurinia Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aurinia Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aurinia Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Aurinia Pharmaceuticals Pair Trading
Aurinia Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Aurinia Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aurinia Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aurinia Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aurinia Pharmaceuticals to buy it.
The correlation of Aurinia Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aurinia Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aurinia Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aurinia Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Aurinia Pharmaceuticals position
In addition to having Aurinia Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Artificial Intelligence Thematic Idea Now
Artificial Intelligence
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
To fully project Aurinia Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Aurinia Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Aurinia Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.